Press Releases | ClavystBio

Press Releases

02 Oct 2025

Portfolio

Cirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMD

10 Sep 2025

Portfolio

Eyexora Launches the First Hub-and-Spoke Model for Accelerating Ophthalmology Innovation

13 Aug 2025

Portfolio

65LAB awards US$1.5 million to Duke-NUS platform to advance antifibrotic drug discovery

23 Jul 2025

Portfolio

Respiree Closes US$11.6m Series A Financing Round Led by We Venture Capital and Clavystbio

17 Jun 2025

Portfolio

Nuevocor Strengthens Board with Appointment of Thierry Abribat

11 Jun 2025

Portfolio

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

10 Jun 2025

ClavystBio

ClavystBio and ASTAR Partner to Grow MedTech Ventures in Singapore

05 Jun 2025

Portfolio

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management

03 Mar 2025

Portfolio

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

22 Jan 2025

Portfolio

CoV Biotechnology Takes Next Step to Become Leyden Labs Asia, Advancing its Mission to Combat Respiratory Infectious Diseases

Stay in the Loop

Sign up to get the latest news on our innovation community and events.

Subscribe Now